Literature DB >> 32375806

Reappraisal on pharmacological and mechanical treatments of heart failure.

Bo Liang1, Yu-Xiu Zhao2, Xiao-Xiao Zhang1, Hui-Ling Liao2,3, Ning Gu4.   

Abstract

Heart failure (HF) is a highly frequent disorder with considerable morbidity, hospitalization, and mortality; thus, it invariably places pressure on clinical and public health systems in the modern world. There have been notable advances in the definition, diagnosis, and treatment of HF, and newly developed agents and devices have been widely adopted in clinical practice. Here, this review first summarizes the current emerging therapeutic agents, including pharmacotherapy, device-based therapy, and the treatment of some common comorbidities, to improve the prognosis of HF patients. Then, we discuss and point out the commonalities and areas for improvement in current clinical studies of HF. Finally, we highlight the gaps in HF research. We are looking forward to a bright future with reduced morbidity and mortality from HF.

Entities:  

Keywords:  Comorbidities; Devices; Heart failure; Management; Pharmacotherapy; Prognosis; Treatment

Year:  2020        PMID: 32375806     DOI: 10.1186/s12933-020-01024-5

Source DB:  PubMed          Journal:  Cardiovasc Diabetol        ISSN: 1475-2840            Impact factor:   9.951


  7 in total

Review 1.  Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism.

Authors:  Bo Liang; Rui Li; Peng Zhang; Ning Gu
Journal:  J Cardiovasc Transl Res       Date:  2022-08-15       Impact factor: 3.216

Review 2.  Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure.

Authors:  Bo Liang; Ning Gu
Journal:  Cardiovasc Diabetol       Date:  2022-05-27       Impact factor: 8.949

3.  Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction.

Authors:  Bo Liang; Yi Liang; Ning Gu
Journal:  BMC Cardiovasc Disord       Date:  2022-06-10       Impact factor: 2.174

Review 4.  Advances in Exosomes Derived from Different Cell Sources and Cardiovascular Diseases.

Authors:  Bo Liang; Xin He; Yu-Xiu Zhao; Xiao-Xiao Zhang; Ning Gu
Journal:  Biomed Res Int       Date:  2020-07-07       Impact factor: 3.411

5.  Comparative Safety and Efficacy of Eight Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

Authors:  Bo Liang; Yong-Chun Zhu; Ning Gu
Journal:  Front Cardiovasc Med       Date:  2022-03-21

Review 6.  Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.

Authors:  Bo Liang; Ning Gu
Journal:  Int J Med Sci       Date:  2022-06-21       Impact factor: 3.642

7.  Activation of the sigma-1 receptor exerts cardioprotection in a rodent model of chronic heart failure by stimulation of angiogenesis.

Authors:  Xin Zhao; Xin Liu; Xiuhuan Chen; Xueyu Han; Yazhou Sun; Yuhong Fo; Xiukun Wang; Chuan Qu; Bo Yang
Journal:  Mol Med       Date:  2022-08-03       Impact factor: 6.376

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.